Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT01011972 | A Study of Intravenous XMT-1107 in Patients With Advanced Solid Tumors | PHASE1 | COMPLETED | 52 | — | — | Mar 1, 2010 | Sep 1, 2013 | Jan 31, 2018 | 4 | United States |
| Arm | Type | Description |
|---|---|---|
| XMT-1107 | EXPERIMENTAL | Dose escalation groups of XMT-1107, I.V. (in the arm) beginning at 6 mg/m\^2, doubling in dose to 24 mg/m\^2, then 40 mg/m\^2, then 60 mg/m\^2, then 80 mg/m\^2 with subsequent doses at 33% of the previous until disease progression or unacceptable side effects are experienced. |
| Name | Type | Description |
|---|---|---|
| XMT-1107 | DRUG | 6 mg XMT-1107 administered by I.V. (in the vein) administered over 90 min, once every 21 days : until progression or unacceptable toxicity develops |
Inclusion Criteria: * Patient must have a histological diagnosis of advanced solid tumor and must be refractory to standard therapy or have no effective therapy. * Measurable or evaluable disease. * At least 42 days since administration of mitomycin or nitrosoureas and 28 days since any other chemo...